BOULDER, Colo.--(BUSINESS WIRE)--BaroFold, Inc., a biopharmaceutical company developing “BioBetter” protein therapeutics, announced today the appointment of J. William Freytag, Ph.D. as President and Chief Executive Officer.
“We are delighted to attract a leader with such an outstanding record of success,” stated Kyle Lefkoff, General Partner of Boulder Ventures and Chairman of BaroFold’s Board of Directors. “BaroFold is making excellent progress on the development of its pipeline of protein therapeutics, and Bill’s exceptional track record will help capitalize on our opportunity to make BaroFold a leading company in the fast emerging BioBetter protein therapeutic field.”
“I am truly excited to join such a talented team that has produced excellent progress exploiting its proprietary protein folding technology (PreEMT™) for the development of next generation follow-on protein therapeutics,” stated Dr. Freytag, CEO. “This dynamic company offers an exceptional opportunity to deliver improved and novel protein therapeutics.”
As BaroFold’s new President and CEO, Dr. Freytag brings more than 25 years of experience in the biotechnology and pharmaceutical industries. Most recently, Dr. Freytag served as Chairman and CEO of Aspreva Pharmaceuticals, Inc. from July 2007 until its merger with Galenica AG in January 2008. Previously, Dr. Freytag served as Chairman and CEO of Myogen, Inc. from July 1998 until it was acquired by Gilead Sciences, Inc. in November 2006. Prior to Myogen, Dr. Freytag held senior executive roles with Somatogen, Inc., a biopharmaceutical company where he was responsible for corporate and commercial development, and at Boehringer Mannheim Corporation, where he served as President of Research and Development. Dr. Freytag spent 10 years with DuPont Medical Products in various research and business positions. In addition to his role at BaroFold, Dr. Freytag currently serves as the chairman of the board for BiOptix LLC and is also serving on the Board of Directors of GlobeImmune, Inc., Sierra Neuropharmaceuticals, Inc., and ARCA Biopharma, Inc. He earned his Ph.D. in biochemistry from the University of Kansas Medical Center.
BaroFold is developing improved and novel biopharmaceuticals targeting validated disease pathways with blockbuster potential utilizing its proprietary process technologies. www.barofold.com.
This press release contains forward-looking statements that involve risks and uncertainties, including statements relating to initiation and progress of the Company's clinical trial programs. Actual results could differ materially from those projected and the Company cautions investors not to place undue reliance on the forward-looking statements contained in this release.
Julia Kendall, 303-545-0358
Business Communications Manager